乳腺癌新辅助化疗前后分子标志物表达的临床意义

Clinical significance of molecular markers expression before and after neoadjuvant chemotherapy of breast cancer

目的探讨乳腺癌新辅助化疗前后分子标志物表达的临床意义。方法应用免疫组化方法检测40例乳腺浸润性导管癌Ⅱ～Ⅲ期患者在新辅助化疗前后分子标志物的表达情况,分析其改变原因及分子标志物与临床疗效的相关性。结果 40例患者新辅助化疗前后分子标志物(ER、PR、Ki-67、C-erbB-2、pS2)均发生了一定程度的量变和状态改变,ER和Ki-67表达的改变与新辅助化疗的临床疗效相关(P<0.05)。结论 ER和Ki-67表达可以作为预测化疗疗效的敏感因子。

Objective To explore the clinical significance of molecular markers expression before and after neoadjuvant chemotherapy of breast cancer.Methods Molecular markers expression before and after neoadjuvant chemotherapy among 40 cases of patients with invasive ductal carcinoma of stage Ⅱ-Ⅲ was tested by immunohistochemistry method.The changes reasons and correlation between molecular markers and clinical effect were analyzed.Results After neoadjuvant chemotherapy,biological molecular markers of 40 patients（ER,PR,C-erbB-2,Ki-67 and pS2） all had some quantitative and status changes,and the changes of ER,Ki-67 expression were correlated with clinical effect（P 0.05）.Conclusion ER and Ki-67 expression can be used to predict the sensitivity of chemotherapy curative effect.